These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 33057628

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J, Min KL, Kang S, Yang S, Park MS, Wi J, Chang MJ.
    Microbiol Spectr; 2021 Dec 22; 9(3):e0063321. PubMed ID: 34937189
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.
    Wenzler E, Butler D, Tan X, Katsube T, Wajima T.
    Clin Pharmacokinet; 2022 Apr 22; 61(4):539-552. PubMed ID: 34792787
    [Abstract] [Full Text] [Related]

  • 6. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
    Natesan S, Pai MP, Lodise TP.
    J Antimicrob Chemother; 2017 Oct 01; 72(10):2813-2816. PubMed ID: 29091209
    [Abstract] [Full Text] [Related]

  • 7. Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa.
    Pilmis B, Petitjean G, Lesprit P, Lafaurie M, El Helali N, Le Monnier A, on behalf the ATB PK/PD study group.
    Eur J Clin Microbiol Infect Dis; 2019 Aug 01; 38(8):1457-1461. PubMed ID: 31073653
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Ex vivo Ceftolozane/Tazobactam Clearance during Continuous Renal Replacement Therapy.
    Chaijamorn W, Shaw AR, Lewis SJ, Mueller BA.
    Blood Purif; 2017 Aug 01; 44(1):16-23. PubMed ID: 28237981
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
    Awissi DK, Beauchamp A, Hébert E, Lavigne V, Munoz DL, Lebrun G, Savoie M, Fagnan M, Amyot J, Tétreault N, Robitaille R, Varin F, Lavallée C, Pichette V, Leblanc M.
    Pharmacotherapy; 2015 Jun 01; 35(6):600-7. PubMed ID: 26095008
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cefepime Population Pharmacokinetics and Target Attainment in Critically Ill Patients on Continuous Renal Replacement Therapy.
    Al-Shaer MH, Philpott CD, Droege CA, Courter JD, Healy DP, Droege ME, Ernst NE, Mueller EW, Peloquin CA.
    Antimicrob Agents Chemother; 2021 May 18; 65(6):. PubMed ID: 33722885
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.